Netherlands· NL-e424da0dc015
NGENLA 60 mg/1,2 ml, oplossing voor injectie
A somatrogon product containing somatrogon, registered in Netherlands by Pfizer Europe MA EEIG. The same ATC class is registered in 14 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Somatrogon is registered in 14 of 19 countries.
Countries holding a registration under ATC H01AC08 (somatrogon), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 9 of them publish a price we can compare per daily dose
Somatrogon · ATC H01AC08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of somatrogon costs, country by country.
Normalised to the WHO defined daily dose (2.4 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Somatrogon · price per daily dose (2.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$38.71
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SOMATROGON
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Netherlands (NL)
- ATC code
- H01AC08
- ATC class
- Somatrogon
- Defined daily dose
- 2.4 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1617
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Somatrogon in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesNgenlaPfizer Laboratories Div Pfizer Inc
- IrelandNGENLA 60 mg/ 1.2 ml Solution for injectionPfizer Europe MA EEIG
- CanadaNGENLAPFIZER CANADA ULC
- SwitzerlandNgenla 24 mg/ 1.2 ml, Injektionslösung im FertigpenPfizer AG
- CzechiaNGENLAPfizer Europe MA EEIG, Bruxelles
- SpainNGENLA 24 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAPfizer Europe Ma Eeig
- FinlandNgenlaPfizer Europe MA EEIG
- FranceNGENLA 24 mg, solution injectable en stylo prérempliPFIZER EUROPE MA EEIG (BELGIQUE)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ngenla
- Liechtenstein · Ngenla
- Norway · Ngenla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/020272c3-9f83-4b94-ab4d-555a1f05e80d GET /v1/drugs/020272c3-9f83-4b94-ab4d-555a1f05e80d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ngenla-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Somatrogon",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127969",
"excipients": [
"CITROENZUUR 1-WATER (E 330)",
"HISTIDINE, (L-)",
"METACRESOL",
"NATRIUMCHLORIDE",
"POLOXAMEER 188",
"TRINATRIUMCITRAAT 2-WATER (E 331)",
"WATER VOOR INJECTIE"
],
"substances": [
"SOMATROGON"
],
"leaflet_url": null,
"authorised_at": "2022/02/14",
"procedure_number": "EMEA/H/C/005633",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1617",
"additional_monitoring": "Y"
}See everything about somatrogon.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.